The future of the UK life sciences sector: Balancing innovation and regulation
An overview of some important upcoming legal and policy developments in the UK for life sciences organisations
February 26, 2024
The future of the UK life sciences sector: Balancing innovation and regulationAn overview of some important upcoming legal and policy developments in the UK for life sciences organisationsFebruary 26, 2024 Why should I read this?The life sciences sector is one of the UK’s most successful sectors, reported to be worth over £90 billion. It is also a key growth sector for the UK economy, with the Government having recently announced a £650 million “war chest” to boost the sector as part of its “Life Sci for Growth” package and make the UK one of the best jurisdictions worldwide for innovators and investors alike. The life sciences sector is also receiving renewed attention in political circles ahead of the general election later this year with both Labour and Conservative parties pledging to ‘turbocharge’ pharmaceutical R&D in the UK. These reforms come at a time when the EU pharmaceutical regulatory framework is also set to undergo significant changes. Alongside investment commitments, some important regulatory developments are expected to impact organisations operating in the UK life sciences sector over the coming months. We discuss the key elements of those developments in this briefing – an overarching theme is the Government’s desire to empower UK innovation and growth in a series of target initiatives. What changes can we expect to see in the UK?UK clinical trialsWe can expect to see new regulations governing UK clinical trials by the end of March 2024. This is in line with the 2023-2024 Business Plan of the MHRA, the UK’s healthcare regulator. The new regulations are expected to incorporate learnings from the Lord O’Shaughnessy review into UK clinical trials, as well as a risk-appropriate (i.e. low/medium/high) approach to assessing new clinical trial applications with a view to avoiding any further MHRA backlogs whilst maintaining patient safety and public trust. In addition, the MHRA has recently announced a notification scheme for low-risk trials such that a full regulatory assessment is not required. Of notable importance are additional means to increase patient awareness of and participation in clinical trials – for example by conducting decentralised clinical trials and/or pooling data. Whilst these are already carried out in the UK, they are supported by fragmented guidance – this may be contrasted with other jurisdictions such as Denmark, for example, for which clear, purpose-built guidance exists. The MHRA has communicated a desire to work with industry to shape guidance in these areas for the UK. Market accessMarket access remains a challenge for pharmaceutical companies looking to introduce new products in to the UK market. With this in mind, the Government has identified a couple of specific initiatives to streamline some of the processes and expedite certain applications. International recognitionFrom 1 January 2024, the EC Decision Reliance Procedure (which allowed the MHRA to rely on decisions made by the European Commission when assessing an application for a GB marketing authorisation) has been replaced by the MHRA’s own International Recognition Procedure (IRP). The IRP allows the MHRA to leverage the decisions and expertise of “reference regulators” in seven other jurisdictions (Australia, Canada, Switzerland, Singapore, Japan, the USA and the EU) when assessing marketing authorisation applications for the benefit of UK patients (despite the MHRA retaining ultimate discretion). The IRP allows for two recognition timescales (depending on certain eligibility criteria to be specified at the time of application), Recognition A or Recognition B, at 60 and 110 days respectively. It should be noted that, whilst international recognition can cut months from development timelines, the timescales for issuing reimbursement guidance are unaffected. This presents another reason for developers to consider engaging with relevant stakeholders at an early stage to minimise any delays to market. Innovative pathwaysInnovators are encouraged to utilise the various innovative medicine pathways available to them which, alongside the IRP, the MHRA hopes will help to establish the UK’s “unique selling point” as a pragmatic jurisdiction for the innovation and marketing of medicines. These include:
Branded medicines pricingThe 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) came into effect on 1 January 2024 and is due to run until 31 December 2028. The success of VPAG, which replaces the 2019 voluntary scheme for branded medicines pricing and access (VPAS), will be measured against three key objectives: promoting better patient outcomes and a healthier population, supporting UK economic growth and contributing to a financially sustainable NHS. Point of care manufactureDraft regulations and guidance to govern point of care manufacturing are expected to land in March 2024, which the MHRA hopes will increase the availability of novel medicines for patients (often where no other treatments options are suitable or available). Regulation of novel technologiesAs with many other sectors, AI remains at the centre of innovation in the medical technology space, with potential uses spanning from triaging patients in hospitals through to enhanced analytical diagnostic techniques and wearable medical devices. Whilst the regulation of AI pervades all uses of the technology, some key issues to be managed in the healthcare sector include the following:
For further thoughts on the application of AI in medical technologies, please see our white paper 'How healthcare regulation and data protection laws are shaping the future of telemedicine'. Medical devicesA widescale reform of the UK medical devices regime is ongoing, with the MHRA having recently published a roadmap towards the future regulatory framework. The MHRA intends to deliver the regulations on a phased basis, with priority measures to enhance post-market surveillance expected this year and other core elements (including a rehaul of the classification system and new requirements relating to cybersecurity, labelling, instructional materials and clinical investigations) to follow in 2025. Stakeholder discussions on the proposed regulations are expected to take place in the first half of this year with future core regulations to be published later in the year. We have already seen a transitional shift from CE marking to UKCA marking, as well as some consolidated guidance on software and AI as a medical device, clarifying outputs from the MHRA’s Software Group. It is intended that the revised regulations and guidance will sit alongside the IDAP and international recognition routes as part of a clear, comprehensive framework to assist innovators in getting their products to market and managing patient safety through effective vigilance. An opposition viewpointAmongst the various plans and announcements by the incumbent Conservative Government, the Labour party has recently published its own plan for the UK’s life sciences sector which it hopes can deliver an additional annual investment of £10 billion into R&D, as well as 100,000 extra jobs in the sector by 2030. The plan includes:
How does this compare to the EU?In addition to the changes to come in the UK, there are also changes to come in the EU, including concerning clinical trials, market access, the regulation of novel technologies and the EU MDR/IVDR. The implementation and impact of the Clinical Trials Regulation (CTR) continues to harmonize clinical trial procedures throughout the EU. Ongoing efforts are dedicated to enhancing transparency, prioritizing patient safety, and upholding data integrity in clinical research practices. With regard to market access, the European Commission intends to modernize the pharmaceutical sector by prioritizing a patient-focussed approach, which is simultaneously supposed to foster an innovative and competitive environment. The aims are establishing a Single Market for medicines, streamlining administrative processes to expedite patient access, ensuring affordability, addressing medicine shortages, and promoting environmental sustainability. Another focus will be on combating antimicrobial resistance (AMR) and enhancing transparency regarding public funding for medicine development. The year 2024 will be crucial as the European Parliament and the Council engage in the approval process. Another focus of the EU lies on the adoption of the AI Act to ensure improved circumstances for the advancement and utilization of AI. This will have an enormous impact on the sector as it will likely affect the majority of AI systems utilized in medical devices. Furthermore, in January 2024 the European Commission proposed to take additional steps to amend the transitional periods in the EU MDR and the EU IVDR. Efforts to launch parts of EUDAMED aim at enhancing transparency and protecting patient care. Finally, measures are considered to oblige manufacturers to promptly notify healthcare systems of supply disruptions for certain medical devices and in vitro diagnostics in order for such to take respective measures. It remains to be seen whether current actions by members of the European Parliament demanding a wider reform of the EU MDR/IVDR will result in any changes. What does this mean for me?It is an exciting time for the life sciences sector across Europe, with disruptive technologies continuing to emerge and numerous regulatory changes on the horizon due to impact organisations within the coming months. This could mean new ways of working and/or additional compliance requirements. These developments are also likely to have knock-on effects and/or be influenced by other measures. For example, organisations may consider a shift to decentralised clinical trials in an attempt to realise ESG targets, with the availability and conduct of those trials influenced by the availability and capability of AI and other digital health technologies. As NHS and private organisations’ data governance strategies are developed we may also see increased reliance on, and capability of, these digital technologies. As with other sectors, public sector resourcing also continues to play a role and influence timings and decision making processes. All of this means that, whatever their role in the life sciences sector, organisations across Europe need to closely monitor these reform initiatives as they make their way through the legislative process over the coming 12-18 months.
Further readingKey contacts
Latest InsightsLatest News
Latest Events
legal updates November 18, 2026 UK: FCA releases new ESG ratings rules legal updates November 18, 2026 UK: AI Transcription – harness benefits, manage risks legal updates November 18, 2026 Commercially Connected shorts - 18 November 2026 legal updates November 18, 2026 COP31: Oceans, nature and land use gain ground in climate policy and inves... deal alerts November 06, 2026 Eversheds Sutherland advises Mercedes-Benz on European fast-charging partne... firm news November 05, 2026 Eversheds Sutherland hires partner Peter Cheng to lead Hong Kong ECM practi... firm news October 27, 2026 Eversheds Sutherland (International) announces senior leadership appointmen... firm news October 26, 2026 Eversheds Sutherland deepens fintech and regulatory bench with double partn... hybrid Europe Action Week 2026 Europe Action Week returns this November with a dynamic mix of events designed to help you navigate what’s next. in-person Industrial relations masterclass November 18, 2026 9.30am - 4.30pm (GMT) London, United Kingdom virtual Education Webinar - Equality, diversity and inclusion: current developments... November 18, 2026 11:00AM - 12:00PM virtual Education Webinar - Protecting your IP when contracting with third parties ... November 19, 2026 11:00AM - 12:00PM |